Abbott Laboratories Stock Declines Despite $21 Billion Acquisition and Strategic Initiatives
Trendline

Abbott Laboratories Stock Declines Despite $21 Billion Acquisition and Strategic Initiatives

What's Happening? Abbott Laboratories (NYSE:ABT) has experienced a significant stock decline in 2026, falling 17.79% from $125.29 at the end of 2025 to $103.00. This underperformance contrasts with the S&P 500's 1.16% gain over the same period. The healthcare giant's shares continued to fall despite
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.